

1 **A Network Medicine Approach to Investigating ME/CFS Pathogenesis** 2 **in Severely Ill Patients: A Pilot Study**

3 Li-Yuan Hung^{1†}, Chan-Shuo Wu^{1†}, Chia-Jung Chang², Peng Li¹, Kimberly Hicks³, Becky Taurog⁴,
4 Joshua J Dibble¹, Braxton Morrison¹, Chimere L Smith⁴, Ronald W Davis², Wenzhong Xiao¹

5 ¹ Computational Research Center for Complex Chronic Diseases, Massachusetts General Hospital,
6 Harvard Medical School, Boston, MA 02114, USA;

7 ² ME/CFS Collaborative Research Center, Stanford University School of Medicine, Palo Alto, CA
8 94304, USA;

9 ³ Open Medicine Foundation;

10 ⁴ Patient Led Research Collaborative.

11

12 [†]The authors contributed equally to this work.

13 *** Correspondence:**

14 Corresponding Author

15 Wenzhong.Xiao@mgh.harvard.edu

16 **Keywords:** Network Medicine, ME/CFS, Chronic Fatigue Syndrome, Neuroimmunology,
17 Neurodegenerative Diseases, Cognitive Disorders, PPI Network Analysis, Long COVID

18 **Abstract**

19 This pilot study harnessed the power of network medicine to unravel the complex pathogenesis of
20 Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). By utilizing a network analysis
21 on whole genome sequencing (WGS) data from the Severely Ill Patient Study (SIPS), we identified
22 ME/CFS-associated proteins and delineated the corresponding network-level module, termed the
23 SIPS disease module, together with its relevant pathways. This module demonstrated significant
24 overlap with genes implicated in fatigue, cognitive disorders, and neurodegenerative diseases. Our
25 pathway analysis revealed potential associations between ME/CFS and conditions such as COVID-
26 19, Epstein-Barr virus (EBV) infection, neurodegenerative diseases, and pathways involved in
27 cortisol synthesis and secretion, supporting the hypothesis that ME/CFS is a neuroimmune disorder.
28 Additionally, our findings underscore a potential link between ME/CFS and estrogen signaling
29 pathways, which may elucidate the higher prevalence of ME/CFS in females. These findings provide
30 insights into the pathogenesis of ME/CFS from a network medicine perspective and highlight
31 potential therapeutic targets. Further research is needed to validate these findings and explore their
32 implications for improving diagnosis and treatment.

33

34 1 Introduction

35 Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex and debilitating
36 condition characterized by persistent fatigue, cognitive impairments, post-exertional malaise, and a
37 variety of other symptoms that severely impact patients' quality of life (Cortes Rivera et al., 2019).
38 Notably, the condition predominantly affects women (Lim et al., 2020). Despite extensive research,
39 the etiology of ME/CFS remains elusive, and effective treatments are still lacking. Recent evidence
40 suggests that neuroimmune dysfunction plays a crucial role in the pathogenesis of ME/CFS
41 (Marshall-Gradisnik and Eaton-Fitch, 2022; Morris and Maes, 2013a, 2013b; Ryabkova et al., 2022).

42
43 Genetic factors are believed to contribute significantly to ME/CFS, with prior studies suggesting a
44 genetic predisposition to the disease (Afari and Buchwald, 2003; Albright et al., 2011). However, the
45 specific genes and pathways involved have not been fully elucidated (Dibble et al., 2020). This study
46 employs a network medicine approach to investigate the genetic underpinnings of ME/CFS, focusing
47 on its most severe manifestations.

48
49 Approximately 25% of ME/CFS patients are severely ill and are often housebound or bedridden
50 (Feiden, 1990; Fennell et al., 1998; Pendergrast et al., 2016). Our research centers on the Severely Ill
51 Patient Study (SIPS) cohort, which includes patients enduring the most severe symptoms of ME/CFS
52 (Chang et al., 2021). These individuals suffer from profound fatigue, cognitive impairment, and a
53 significantly reduced quality of life. Previous analyses of this cohort revealed unique sleep profiles,
54 cognitive deficits, and markedly low morning cortisol levels. Additionally, parallels between
55 ME/CFS and long COVID symptoms suggest common etiological pathways (Chang et al., 2021).
56 The credibility of the SIPS cohort is reinforced by its validation by medical professionals, ensuring
57 the authenticity and representativeness of the data.

58
59 The network medicine approach provides a sophisticated framework for understanding disease
60 mechanisms at the molecular level. This paradigm introduces the concept of *disease modules*,
61 interconnected subgraphs within the protein-protein interaction (PPI) network that represent the
62 molecular facets of specific conditions. By examining these modules, researchers can predict disease
63 relationships and elucidate the molecular mechanisms underlying complex diseases (Barabási et al.,
64 2011; Menche et al., 2015; Sharma et al., 2015).

65
66 By harnessing the power of PPI network analysis and whole genome sequencing (WGS), we
67 identified pathways potentially contributing to ME/CFS development. Our findings suggest
68 significant involvement of the immune and neurological systems, indicating shared genetic
69 underpinnings with these systems.

70
71 In summary, this study sheds light on the genetic landscape of ME/CFS, providing new insights and
72 potentially paving the way for novel therapeutic interventions. Our findings, particularly those related
73 to immune and neurological pathways, could reshape our understanding of ME/CFS and lead to more
74 targeted treatment strategies.

75 2 Results

76 In the Severely Ill Patient Study (SIPS) (Chang et al., 2021), we investigated the medical conditions
77 of 20 ME/CFS patients exhibiting severe symptoms, as previously documented. These individuals
78 met the International Consensus Criteria for ME/CFS (ME-ICC) (Carruthers et al., 2011) and were
79 confined to their homes, remaining sedentary and reclined for over 14 hours daily. Their SF-36
80 physical functioning scores and Karnofsky Performance Status Index (Karnofsky and Burchenal,
81 1949) scores were both below 70.

82
83 WGS was performed on the blood samples from the 20 SIPS patients, and high-confidence variants
84 were filtered based on several criteria (see Methods), resulting in 2,798,019 variants for further
85 analysis. Using the American College of Medical Genetics and Genomics (ACMG) criteria, we
86 identified 103 pathogenic or likely pathogenic variants (Qiagen IVA). These were then compared to
87 background population data, leading to the removal of 7 common SNVs. The remaining 96 variants
88 were aggregated at the gene level (Table S1). Among them, 9 genes were found to affect at least 2
89 (10%) of the 20 patients (Figure 1, Table S1).

90
91 We examined the nine genes with recurrent variants in the SIPS patients (Figure 1), specifically
92 *ACADL*, *BRCA1*, *CFTR*, *COX10*, *HABP2*, *MFRP*, *PCLO*, *PRKN*, and *ZFPM2*. Given the defining
93 characteristic of cognitive abnormalities in SIPS patients, it was crucial to assess the relevance of
94 these genes to their symptoms. Seven of the nine genes (77.8%) have previously been linked to
95 cognitive impairment or neurological functions. For instance, *BRCA1* is involved in maintaining
96 genomic stability and has implications in neurodegeneration and stress-induced senescence (Leung
97 and Hazrati, 2021; Suberbielle et al., 2015). The *PRKN* gene is associated with Parkinson's disease,
98 characterized by both motor and non-motor symptoms (Lücking et al., 2000). *CFTR*'s expression in
99 the nervous system may influence mood, memory, energy balance, olfaction, motor function,
100 respiration, and autonomic control of visceral organs (Reznikov, 2017). Mutations in the *COX10*
101 gene, crucial for cellular respiration, have been linked to various peripheral neuropathy disorders
102 (Fünfschilling et al., 2012; Kuroha et al., 2022). *MFRP* is tied to eye development, with mutations
103 affecting retinal microglia (Kumari et al., 2022). *PCLO*, encoding the Piccolo protein essential for
104 synaptic transmission, has mutations linked to pontocerebellar hypoplasia, a rare neurodegenerative
105 disorder (Ackermann et al., 2019; Ahmed et al., 2015). *ZFPM2* is involved in the development of
106 GABAergic neurons in specific brain regions (Morello et al., 2020).

107
108 Our results suggest a connection between the identified pathogenic variants and cognitive symptoms
109 in the SIPS patients. While further studies are required to elucidate how these genes influence
110 cognitive impairment in the SIPS patients, Figure 1 provides a valuable foundation for future
111 investigations.

112
113 To investigate the genetic factors contributing to the onset and progression of ME/CFS in severely ill
114 patients, we utilized a network-based approach that considers the interconnections between disease-
115 related genes. This approach aims to identify and locate the SIPS disease module within the human
116 PPI network and discern its interplay with other pathways or conditions. During the network

117 construction process, emphasis is placed on relevant genes, as disease-associated genes tend to
118 cluster together, forming interconnected subnetworks, while unrelated genes scatter randomly and
119 minimally influence the subnetwork's structure (Menche et al., 2015).

120

121 Applying the Disease Module Detection (DIAMOND) algorithm (Ghiassian et al., 2015), we
122 successfully inferred the SIPS disease module by starting with a subgraph of seed genes derived from
123 96 pathogenic or likely pathogenic variants identified in the 20 SIPS patients (Table S1). Using this
124 set of seed genes as the input, the DIAMOND algorithm identified the top 200 neighborhoods,
125 forming the SIPS disease module (for details, refer to Table S2). Within the disease module, we
126 noted a significant presence of genes related to fatigue and cognitive disorders. Using the disease-
127 gene association data from DisGeNET (Piñero et al., 2020) as a reference, genes linked to fatigue
128 exhibited a 3.94-fold enrichment (p-value: 1.3899e-14, cumulative hypergeometric test), while those
129 connected to cognitive disorders showed a 2.29-fold enrichment (p-value: 0.0005) (Figure 2A).
130 Furthermore, the SIPS disease module was found to intertwine with the six neurodegenerative
131 disease pathways in KEGG (Kanehisa et al., 2023) (Figure 2A, 2B), with enrichment ranging from
132 2.48 to 4.61 fold (Figure 2A).

133

134 Considering the widespread cognitive abnormalities in severely ill ME/CFS patients and the
135 unresolved questions surrounding the underlying mechanisms of these conditions, the intersection of
136 the SIPS disease module with neurological disease pathways is especially noteworthy.

137

138 In our subsequent analysis, we compared the SIPS disease module with the 70 disease modules
139 presented in the DIAMOND publication (Ghiassian et al., 2015). These 70 diseases were classified
140 into 4 distinct categories based on their conceivable links to the hypothesized mechanisms of
141 ME/CFS (Marshall-Gradisnik and Eaton-Fitch, 2022). A fifth category, cancer, was incorporated as
142 an out-group for comparative purposes. Our findings revealed that certain diseases exhibited
143 similarities with the SIPS disease module, as depicted in Figure 3A. Notably, nearly half of the top
144 20 diseases showing the greatest resemblance were either entirely or partially neurological disorders.
145 These included conditions such as muscular dystrophies, basal ganglia diseases, spinocerebellar
146 degenerations, Charcot–Marie–Tooth disease, motor neuron disease, cerebrovascular disorders,
147 amyotrophic lateral sclerosis (ALS), and cerebellar ataxia. In contrast, cancer disease modules
148 showed minimal similarity to the SIPS disease module.

149

150 When visualizing the SIPS disease module alongside the 70 DIAMOND disease modules in a
151 network diagram, it was evident that the SIPS module closely overlapped with modules related to
152 immune and neurological systems (Figure 3B). The predominance of immune and neurological
153 conditions among the five most similar diseases suggests that the SIPS disease module might share
154 underlying causes with these two systems.

155

156 Our initial analyses offer valuable insights into the genetic makeup of ME/CFS. However, to solidify
157 these findings, it is essential to cross-reference them with data from other ME/CFS cohorts. Thus, we

158 incorporated data from two additional ME/CFS cohorts to enhance the SIPS disease module. The
159 gene sets for these two cohorts were sourced from two distinct research studies:

- 160 1. The 23andMe Cohort: Based on a study published in *Frontiers in Pediatrics* (Perez et al., 2019a),
161 we selected genes containing the 50 most commonly observed SNPs from gene regions in their
162 ME/CFS cohort.
- 163 2. The UK-Nor Cohort: Using findings from a study published in *Brain, Behavior, and Immunity*
164 (Hajdarevic et al., 2022), we focused on the genes proximate to their top 50 candidate variants
165 (as detailed in the Method section).

166 Notably, the initial gene sets from these studies had little overlap with the SIPS seed gene set.
167 However, as the initial gene sets expanded into disease modules, the SIPS disease module overlapped
168 with other ME/CFS disease modules by approximately 40% (Table S3). This degree of overlap is
169 unlikely to occur when overlapping the SIPS disease module with disease modules from random
170 initial seeds (Figure S1).

171
172 Subsequently, we created a network representation for these three disease modules. As a reference
173 point, we also constructed a disease module from a depressive disorder cohort (Howard et al., 2019).
174 The disease modules from the other two ME/CFS cohorts appear to intertwine with the SIPS disease
175 module (Figure 4A). In contrast, the depression disease module shows minimal overlap with the
176 ME/CFS disease modules (Figure 4A). These observations suggest the possibility of shared genetic
177 factors contributing to ME/CFS across different cohorts, and the SIPS disease module may represent
178 a core set of genes implicated in the pathogenesis of ME/CFS.

179
180 This finding is particularly significant in addressing the long-standing stigma surrounding ME/CFS,
181 which has often been misdiagnosed as merely a form of depression. Such misdiagnoses have led to
182 inadequate treatment and lack of proper medical support for ME/CFS patients. The clear distinction
183 between the genetic underpinnings of ME/CFS and depressive disorders underscores the necessity of
184 recognizing ME/CFS as a distinct neuroimmune condition. By elucidating these differences, our
185 study advocates for more accurate diagnosis and targeted therapeutic approaches for ME/CFS,
186 moving away from the erroneous conflation with depression.

187
188 To uncover shared biological components among ME/CFS disease modules, we conducted a multi-
189 gene set analysis using Metascape (Zhou et al., 2019). The results indicated that several pathways,
190 including those related to COVID-19, Epstein-Barr virus (EBV) infection, antigen processing and
191 presentation, and the MAPK signaling pathway, are likely associated with ME/CFS. The top 10
192 biological pathway clusters linked to ME/CFS disease modules are presented in Table 1. Given the
193 well-documented association of ME/CFS with post-viral syndromes and the increasing similarities
194 observed between Long COVID and ME/CFS, these findings are particularly noteworthy (Komaroff
195 and Lipkin, 2023; Ryabkova et al., 2022; Spudich and Nath, 2022). Viral infections, including EBV,
196 have been suggested as potential triggers for ME/CFS (Deumer et al., 2021). Notably, signal
197 impairments in the MAPK pathway in natural killer (NK) cells have been previously reported in
198 ME/CFS patients (Chacko et al., 2016; Huth et al., 2016). Other identified pathways related to
199 various neurodegenerative disorders and thyroid hormone signaling have also been previously

200 associated with ME/CFS (Cortes Rivera et al., 2019; Marshall-Gradisnik and Eaton-Fitch, 2022).
201 Interestingly, while not within the top 10 pathway clusters, the cortisol synthesis and secretion
202 pathway was also enriched (Figure S2). This is particularly noteworthy as alterations in diurnal
203 salivary cortisol rhythm were observed in the SIPS patients in our previous study (Chang et al.,
204 2021).

205
206 On the other hand, the largest intra-cluster network component identified in the multi-gene set
207 analysis was associated with immune response pathways related to infections, such as EBV infection,
208 cytokine signaling, positive regulation of immune response, TNF-alpha/NF-kappa B signaling, and
209 antigen processing and presentation (Figure 4B). The network primarily focused on EBV infection
210 and cytokine signaling, which are known to be connected to ME/CFS (Ariza, 2021; Broderick et al.,
211 2010; Maes et al., 2022). These findings further emphasize the potential role of immune
212 dysregulation in the pathogenesis of this disease.

213 **3 Methods**

214 **3.1 Whole genome sequencing (WGS) data generation**

215 WGS was performed for the 20 SIPS ME/CFS patients. Blood samples were obtained from these
216 patients for genomic DNA extraction. The extracted DNA samples were then sequenced on an
217 Illumina NextSeq 500 platform using a 150-bp paired-end sequencing kit.

218 **3.2 Read mapping and variant calling**

219 For each sample, 150-bp paired-end reads were aligned to the human reference genome hg19 using
220 Isaac Genome Alignment Software (Isaac-04.16.09.24). Variant calling was performed using
221 Strelka2 Germline Variant Caller (2.7.1), Manta Structural Variant Caller (1.0.2), and Canvas CNV
222 Caller (1.19.1).

223 **3.3 Variant filtering**

224 High-confidence variants were derived by applying a series of filters as follows:

- 225 1. Variants had to be supported by reads from both strands.
- 226 2. Conflicting variants (i.e., multiple types of variants were called at the same position) were
227 excluded.
- 228 3. Variants located within repetitive regions were excluded.
- 229 4. Variants in the proximity of miscalls were removed to eliminate sequencing errors in specific
230 regions.
- 231 5. To reduce miscalls resulting from in-vitro contaminations or other systematic errors, a
232 reasonable variant must have at least one homozygous sample in which both alleles are
233 consistent with the reference.

234 In total, 2,798,019 high-confidence variants passed these five filters and were subsequently used in
235 the following variant analysis.

236 **3.4 Variant analysis**

237 The high-confidence variants were uploaded to QIAGEN's Ingenuity Variant Analysis (IVA)
238 platform to identify ME/CFS-associated variants. The variant frequencies were compared with
239 background population frequency data from the Exome Aggregation Consortium (ExAC), 1000
240 Genomes Project, and the Genome Aggregation Database (gnomAD).

241
242 Using the ACMG criteria for the interpretation of sequence variants, we identified a total of 103
243 variants as *Pathogenic* or *Likely Pathogenic*. To rule out sporadic findings from variants not yet
244 included in these background databases, we further compared the frequencies of these variants with
245 the Kaviar database, the aforementioned background population data, and the Allele Frequency
246 Community (AFC; <http://www.allelefrequencycommunity.com>), as well as the WGS data of 20
247 randomly selected individuals from the Harvard Personal Genome Project (PGP). Seven of the 103
248 variants were removed because they had an odds ratio of less than 5 in any of these comparisons. The
249 resulting 96 variants (103-7) were aggregated to 93 genes, with 9 genes identified that affect at least
250 2 (or 10%) out of the 20 of the patients.

251 3.5 Network analysis

252 The disease module represents a network that expands from an initial set of genes. In this study, we
253 collected three distinct gene sets. The SIPS gene set served as our primary gene set, while the other
254 two sets were employed for refining or validating our disease module.

- 255 1. The SIPS Gene Set: Derived from the SIPS data, this set was constructed from the 96 identified
256 variants, encompassing 93 genes that house these variants.
- 257 2. 23andMe Gene Set: This set was retrieved from the work of Perez et al. (Perez et al., 2019b),
258 who reported 46 genes associated with ME/CFS. These genes were extracted from the top 50
259 SNPs frequently reported in their ME/CFS cohort, each with C-scores exceeding 10. The
260 23andMe chip versions 4 (~570 k SNPs; prior to August 2017) and version 5 (~640 k SNPs;
261 after August 2017) were used.
- 262 3. UK-Nor Gene Set: Based on Hajdarevic et al.'s study (Hajdarevic et al., 2022), this set was
263 derived from the top 50 variants reported in their Supplementary Table 7. Specifically, these
264 variants were either identified in the overlapping segments of two ME/CFS cohorts or exhibited
265 the lowest p-values in their GWAS analysis. Genes situated within a 500K base pair radius of
266 these variants' linkage disequilibrium (LD) block (with $r^2 \geq 0.5$, as determined by the LDproxy
267 function in LDLink) were chosen to represent this gene set.

268 4 Discussion

269 ME/CFS remains a poorly understood disease, despite its significant impact on patients' quality of
270 life. Our study, focusing on severely ill ME/CFS patients, provides valuable insights into potential
271 genetic factors and pathways that may contribute to the development of this disease.

272
273 Using a network-based approach, we identified several genes and pathways potentially involved in
274 the pathogenesis of ME/CFS, intersecting with the SIPS disease module. This module represents a
275 network implicated in ME/CFS pathogenesis and overlaps with pathways associated with
276 neurological diseases, which is particularly noteworthy given the prevalence of cognitive

277 abnormalities in severely ill ME/CFS patients. Moreover, the recurring DNA variants found in genes
278 linked to cognitive and neurological functions suggest a strong genetic basis for the cognitive
279 irregularities observed in SIPS patients. The overlap of the SIPS disease module with other disease
280 modules related to the immune and neurological systems further supports the hypothesis that
281 ME/CFS is a neuroimmune disorder.

282
283 Our ME/CFS disease modules exhibit a notable enrichment of pathway related to both COVID-19
284 and EBV infection (Table 1). Recent reports suggest that COVID-19 could potentially reactivate
285 EBV, a virus long suspected to play a significant role in the development of ME/CFS (Gold et al.,
286 2021). Interestingly, many symptoms associated with Long COVID are also common in ME/CFS
287 (Komaroff and Lipkin, 2023). This overlap could potentially be linked to the reactivation of EBV in
288 COVID-19 patients. Consequently, inflammation-induced reactivation of EBV may contribute to
289 some of the symptoms observed in long COVID.

290
291 Our analysis also revealed a connection between ME/CFS and estrogen signaling pathways (Table 1).
292 This finding aligns with Perez et al.'s study conducted on the 23andMe cohort, which proposed that
293 certain identified SNPs might participate in hormone-related pathways, including estrogen signaling
294 (Perez et al., 2019a). Given that estrogen is known to regulate innate immune cells and signaling
295 pathways, its potential influence on the pathophysiology of ME/CFS cannot be overlooked (Thomas
296 et al., 2022). This could provide insights into the observed predominance of ME/CFS in females.

297
298 It is noteworthy that among the original 103 variants identified in the severely ill patients, the most
299 prevalent is rs35767802 on the *ADAMTSL2* gene. Although this variant has >12% allele frequency
300 according to AFC population frequency, it was present in at least one allele in 45% (9/20) of the
301 severely affected patients. The *ADAMTSL2* gene is part of the ADAMTS (A Disintegrin and
302 Metalloproteinase with Thrombospondin motifs) family, which plays a crucial role in the degradation
303 of the extracellular matrix and has been linked to various human genetic disorders (Le Goff and
304 Cormier-Daire, 2011). Notably, *ADAMTSL2* is associated with Type VIIC Ehlers–Danlos syndrome
305 (EDS), with a mutation in *ADAMTSL2* recently identified in EDS patients (Desai et al., 2016). There
306 may be a comorbidity between EDS and ME/CFS, as joint hypermobility—a characteristic of EDS—
307 is frequently observed in ME/CFS patients (Eccles et al., 2021).

308
309 In addition, several biological pathways were exclusively identified in the SIPS disease module, as
310 listed in Table S4. These pathways could potentially provide insights into the exacerbation of
311 ME/CFS. However, we found no established connections between these pathways and ME/CFS.
312 Pathways lacking cross-cohort validation, such as these, carry a high degree of uncertainty and may
313 arise from methodological limitations. Therefore, further validation is needed to confirm these
314 connections.

315
316 Overall, this study offers novel insights into the genetic factors that may contribute to severe
317 ME/CFS, identifying several pathways potentially associated with the condition. The discovery of the
318 SIPS disease module and its associated pathways provides a valuable foundation for future research,

319 potentially laying the groundwork for more effective treatments for this debilitating condition.
320 However, these findings are preliminary and, like previous studies, have limitations that necessitate
321 further validation. The accuracy of our findings relies on the current state of the ACMG criteria for
322 variant annotation, which may not be comprehensive. Moreover, while the DIAMOND algorithm is
323 widely used, its effectiveness depends on the completeness and accuracy of the underlying human
324 PPI network data. The potential implications of these findings for the diagnosis and treatment of
325 severe ME/CFS also need to be explored. Future studies should aim to replicate our findings in larger
326 cohorts and to further investigate the potential role of immune and neurological pathways in severe
327 ME/CFS.

328 **5 Author Contributions**

329 WZX and LYH conceived and designed the study. WZX and RWD supervised the project. LYH,
330 CSW, and CJC collected the datasets. LYH, CSW, and CJC performed the data analysis and
331 conducted the statistical analysis. PL, KH, BT, JJD, BM, and CLM contributed to the interpretation
332 of the results. CSW and LYH drafted the manuscript. CSW, LYH, and WZX revised the manuscript.
333 All authors read and approved the final manuscript.

334 **6 Funding**

335 This work was supported by grants from Open Medicine Foundation and Patient Led Research
336 Collaborative (WX).

337 **7 Acknowledgments**

338 We would also like to express our sincere gratitude to each of the severely ill patients who
339 participated in this study.

340 **8 References**

- 341 Ackermann, F., Schink, K.O., Bruns, C., Izsvák, Z., Hamra, F.K., Rosenmund, C., Garner, C.C.,
342 2019. Critical role for Piccolo in synaptic vesicle retrieval. *eLife* 8, e46629.
343 <https://doi.org/10.7554/eLife.46629>
- 344 Afari, N., Buchwald, D., 2003. Chronic fatigue syndrome: a review. *Am. J. Psychiatry* 160, 221–236.
345 <https://doi.org/10.1176/appi.ajp.160.2.221>
- 346 Ahmed, M.Y., Chioza, B.A., Rajab, A., Schmitz-Abe, K., Al-Khayat, A., Al-Turki, S., Baple, E.L.,
347 Patton, M.A., Al-Memar, A.Y., Hurlles, M.E., Partlow, J.N., Hill, R.S., Evrony, G.D.,
348 Servattalab, S., Markianos, K., Walsh, C.A., Crosby, A.H., Mochida, G.H., 2015. Loss of
349 PCLO function underlies pontocerebellar hypoplasia type III. *Neurology* 84, 1745–1750.
350 <https://doi.org/10.1212/WNL.0000000000001523>
- 351 Albright, F., Light, K., Light, A., Bateman, L., Cannon-Albright, L.A., 2011. Evidence for a heritable
352 predisposition to Chronic Fatigue Syndrome. *BMC Neurol.* 11, 62.
353 <https://doi.org/10.1186/1471-2377-11-62>
- 354 Ariza, M.E., 2021. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: The Human
355 Herpesviruses Are Back! *Biomolecules* 11, 185. <https://doi.org/10.3390/biom11020185>
- 356 Barabási, A.-L., Gulbahce, N., Loscalzo, J., 2011. Network medicine: a network-based approach to
357 human disease. *Nat. Rev. Genet.* 12, 56–68. <https://doi.org/10.1038/nrg2918>
- 358 Baron, J. A., Johnson, C. S., Schor, M. A., Olley, D., Nickel, L., Felix, V., Munro, J. B., Bello, S. M.,

- 359 Bearer, C., Lichenstein, R., Bisordi, K., Koka, R., Greene, C., Schriml, L. M., 2024. The DO-
360 KB Knowledgebase: a 20-year journey developing the disease open science ecosystem.
361 *Nucleic Acids Res.* 52(D1):D1305-D1314. <https://doi.org/10.1093/nar/gkad1051>
- 362 Broderick, G., Fuite, J., Kreitz, A., Vernon, S. D., Klimas, N., Fletcher, M. A., 2010. A formal
363 analysis of cytokine networks in chronic fatigue syndrome. *Brain. Behav. Immun.* 24(7).
364 <https://doi.org/10.1016/j.bbi.2010.04.012>
- 365 Carruthers, B.M., van de Sande, M.I., De Meirleir, K.L., Klimas, N.G., Broderick, G., Mitchell, T.,
366 Staines, D., Powles, A.C.P., Speight, N., Vallings, R., Bateman, L., Baumgarten-Austrheim,
367 B., Bell, D.S., Carlo-Stella, N., Chia, J., Darragh, A., Jo, D., Lewis, D., Light, A.R., Marshall-
368 Gradisbik, S., Mena, I., Mikovits, J.A., Murovska, M., Pall, M.L., Stevens, S., 2011. Myalgic
369 Encephalomyelitis: International Consensus Criteria. *J. Intern. Med.* 270(4):327-38.
370 <https://doi.org/10.1111/j.1365-2796.2011.02428.x>
- 371 Chacko, A., Staines, D.R., Johnston, S.C., Marshall-Gradisnik, S.M., 2016. Dysregulation of Protein
372 Kinase Gene Expression in NK Cells from Chronic Fatigue Syndrome/Myalgic
373 Encephalomyelitis Patients. *Gene Regul. Syst. Biol.* 10, 85–93.
374 <https://doi.org/10.4137/GRSB.S40036>
- 375 Chang, C.-J., Hung, L.-Y., Kogelnik, A.M., Kaufman, D., Aiyar, R.S., Chu, A.M., Wilhelmy, J., Li,
376 P., Tannenbaum, L., Xiao, W., Davis, R.W., 2021. A Comprehensive Examination of
377 Severely Ill ME/CFS Patients. *Healthc. Basel Switz.* 9, 1290.
378 <https://doi.org/10.3390/healthcare9101290>
- 379 Cortes Rivera, M., Mastronardi, C., Silva-Aldana, C.T., Arcos-Burgos, M., Lidbury, B.A., 2019.
380 Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Comprehensive Review. *Diagn.*
381 *Basel Switz.* 9, 91. <https://doi.org/10.3390/diagnostics9030091>
- 382 Desai, A., Connolly, J.J., March, M., Hou, C., Chiavacci, R., Kim, C., Lyon, G., Hadley, D.,
383 Hakonarson, H., 2016. Systematic data-querying of large pediatric biorepository identifies
384 novel Ehlers-Danlos Syndrome variant. *BMC Musculoskelet. Disord.* 17, 80.
385 <https://doi.org/10.1186/s12891-016-0936-8>
- 386 Deumer, U.-S., Varesi, A., Floris, V., Savioli, G., Mantovani, E., López-Carrasco, P., Rosati, G.M.,
387 Prasad, S., Ricevuti, G., 2021. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
388 (ME/CFS): An Overview. *J. Clin. Med.* 10, 4786. <https://doi.org/10.3390/jcm10204786>
- 389 Dibble, J.J., McGrath, S.J., Ponting, C.P., 2020. Genetic risk factors of ME/CFS: a critical review.
390 *Hum. Mol. Genet.* 29, R117–R124. <https://doi.org/10.1093/hmg/ddaa169>
- 391 Eccles, J.A., Thompson, B., Themelis, K., Amato, M.L., Stocks, R., Pound, A., Jones, A.-M.,
392 Cipinova, Z., Shah-Goodwin, L., Timeyin, J., Thompson, C.R., Batty, T., Harrison, N.A.,
393 Critchley, H.D., Davies, K.A., 2021. Beyond bones: The relevance of variants of connective
394 tissue (hypermobility) to fibromyalgia, ME/CFS and controversies surrounding diagnostic
395 classification: an observational study. *Clin. Med. Lond. Engl.* 21, 53–58.
396 <https://doi.org/10.7861/clinmed.2020-0743>
- 397 Feiden, K., 1990. *Hope and Help for Chronic Fatigue Syndrome: The Official Guide of the*
398 *CFS/CFIDS Network*, 1st edition. ed. Simon & Schuster, New York.
- 399 Fennell, P.A., Jason, L.A., Klein, S.M., 1998. Capturing the Different Phases of the CFS Illness.
400 *CFIDS Chron.* 11, 13–16.
- 401 Fünfschilling, U., Supplie, L.M., Mahad, D., Boretius, S., Saab, A.S., Edgar, J., Brinkmann, B.G.,
402 Kassmann, C.M., Tzvetanova, I.D., Möbius, W., Diaz, F., Meijer, D., Suter, U., Hamprecht,
403 B., Sereda, M.W., Moraes, C.T., Frahm, J., Goebbels, S., Nave, K.-A., 2012. Glycolytic
404 oligodendrocytes maintain myelin and long-term axonal integrity. *Nature* 485, 517–521.
405 <https://doi.org/10.1038/nature11007>
- 406 Ghiassian, S.D., Menche, J., Barabási, A.-L., 2015. A DIseASE MOdule Detection (DIAMOnD)
407 algorithm derived from a systematic analysis of connectivity patterns of disease proteins in

- 408 the human interactome. *PLoS Comput. Biol.* 11, e1004120.
409 <https://doi.org/10.1371/journal.pcbi.1004120>
- 410 Gold, J.E., Okyay, R.A., Licht, W.E., Hurley, D.J., 2021. Investigation of Long COVID Prevalence
411 and Its Relationship to Epstein-Barr Virus Reactivation. *Pathog. Basel Switz.* 10, 763.
412 <https://doi.org/10.3390/pathogens10060763>
- 413 Hajdarevic, R., Lande, A., Mehlsen, J., Rydland, A., Sosa, D.D., Strand, E.B., Mella, O., Pociot, F.,
414 Fluge, Ø., Lie, B.A., Viken, M.K., 2022. Genetic association study in myalgic
415 encephalomyelitis/chronic fatigue syndrome (ME/CFS) identifies several potential risk loci.
416 *Brain. Behav. Immun.* 102, 362–369. <https://doi.org/10.1016/j.bbi.2022.03.010>
- 417 Howard, D.M., Adams, M.J., Clarke, T.-K., Hafferty, J.D., Gibson, J., Shirali, M., Coleman, J.R.I.,
418 Hagenars, S.P., Ward, J., Wigmore, E.M., Alloza, C., Shen, X., Barbu, M.C., Xu, E.Y.,
419 Whalley, H.C., Marioni, R.E., Porteous, D.J., Davies, G., Deary, I.J., Hemani, G., Berger, K.,
420 Teismann, H., Rawal, R., Arolt, V., Baune, B.T., Dannlowski, U., Domschke, K., Tian, C.,
421 Hinds, D.A., Trzaskowski, M., Byrne, E.M., Ripke, S., Smith, D.J., Sullivan, P.F., Wray,
422 N.R., Breen, G., Lewis, C.M., McIntosh, A.M., 2019. Genome-wide meta-analysis of
423 depression identifies 102 independent variants and highlights the importance of the prefrontal
424 brain regions. *Nat. Neurosci.* 22, 343–352. <https://doi.org/10.1038/s41593-018-0326-7>
- 425 Huth, T.K., Staines, D., Marshall-Gradisnik, S. 2016. ERK1/2, MEK1/2 and p38 downstream
426 signalling molecules impaired in CD56^{dim}CD16⁺ and CD56^{bright}CD16^{dim/-} natural killer cells
427 in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients. *J. Transl. Med.* 14, 97.
428 <https://doi.org/10.1186/s12967-016-0859-z>
- 429 Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M., Ishiguro-Watanabe, M., 2023. KEGG for
430 taxonomy-based analysis of pathways and genomes. *Nucleic Acids Res.* 51, D587–D592.
431 <https://doi.org/10.1093/nar/gkac963>
- 432 Karnofsky, D.A., Burchenal, J.H., 1949. The clinical evaluation of chemotherapeutic agents in
433 cancer, in: MacLeod, C.M. (Ed.), *Evaluation of Chemotherapeutic Agents*. Columbia
434 University Press, New York, pp. 191–205.
- 435 Komaroff, A.L., Lipkin, W.I., 2023. ME/CFS and Long COVID share similar symptoms and
436 biological abnormalities: road map to the literature. *Front. Med.* 10.
- 437 Kumari, A., Ayala-Ramirez, R., Zenteno, J.C., Huffman, K., Sasik, R., Ayyagari, R., Borooah, S.,
438 2022. Single cell RNA sequencing confirms retinal microglia activation associated with early
439 onset retinal degeneration. *Sci. Rep.* 12, 15273. <https://doi.org/10.1038/s41598-022-19351-w>
- 440 Kuroha, Y., Ishiguro, T., Tada, M., Hara, N., Murayama, K., Kawachi, I., Kasuga, K., Miyashita, A.,
441 Hasegawa, A., Takahashi, T., Matsubara, N., Onodera, O., Kakita, A., Koike, R., Ikeuchi, T.,
442 2022. Biallelic COX10 Mutations and PMP22 Deletion in a Family With Leigh Syndrome
443 and Hereditary Neuropathy With Liability to Pressure Palsy. *Neurol. Genet.* 8.
444 <https://doi.org/10.1212/NXG.0000000000200030>
- 445 Le Goff, C., Cormier-Daire, V., 2011. The ADAMTS(L) family and human genetic disorders. *Hum.*
446 *Mol. Genet.* 20, R163-167. <https://doi.org/10.1093/hmg/ddr361>
- 447 Leung, E., Hazrati, L.-N., 2021. Breast cancer type 1 and neurodegeneration: consequences of
448 deficient DNA repair. *Brain Commun.* 3, fcab117.
449 <https://doi.org/10.1093/braincomms/fcab117>
- 450 Lim, E.-J., Ahn, Y.-C., Jang, E.-S., Lee, S.-W., Lee, S.-H., Son, C.-G., 2020. Systematic review and
451 meta-analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis
452 (CFS/ME). *J. Transl. Med.* 18, 100. <https://doi.org/10.1186/s12967-020-02269-0>
- 453 Lücking, C.B., Dürr, A., Bonifati, V., Vaughan, J., De Michele, G., Gasser, T., Harhangi, B.S.,
454 Meco, G., Denèfle, P., Wood, N.W., Agid, Y., Nicholl, D., Breteler, M.M.B., Oostra, B.A.,
455 De Mari, M., Marconi, R., Filla, A., Bonnet, A.-M., Broussolle, E., Pollak, P., Rascol, O.,
456 Rosier, M., Arnould, A., Brice, A., 2000. Association between Early-Onset Parkinson's

- 457 Disease and Mutations in the Parkin Gene. *N. Engl. J. Med.* 342, 1560–1567.
458 <https://doi.org/10.1056/NEJM200005253422103>
- 459 Maes, M., Kubera, M., Kotańska, M., 2022. Aberrations in the Cross-Talks Among Redox, Nuclear
460 Factor- κ B, and Wnt/ β -Catenin Pathway Signaling Underpin Myalgic Encephalomyelitis and
461 Chronic Fatigue Syndrome. *Front. Psychiatry* 13, 822382.
462 <https://doi.org/10.3389/fpsyt.2022.822382>
- 463 Marshall-Gradisnik, S., Eaton-Fitch, N., 2022. Understanding myalgic encephalomyelitis. *Science*
464 377, 1150–1151. <https://doi.org/10.1126/science.abo1261>
- 465 Menche, J., Sharma, A., Kitsak, M., Ghiassian, S., Vidal, M., Loscalzo, J., Barabási, A.-L., 2015.
466 Uncovering disease-disease relationships through the incomplete human interactome. *Science*
467 347, 1257601. <https://doi.org/10.1126/science.1257601>
- 468 Morello, F., Borshagovski, D., Survila, M., Tikker, L., Sadik-Ogli, S., Kirjavainen, A., Estartús, N.,
469 Knaapi, L., Lathi, L., Törönen, P., Mazutis, L., Delogu, A., Salminen, M., Achim, K., &
470 Partanen, J., 2020. Molecular Fingerprint and Developmental Regulation of the Tegmental
471 GABAergic and Glutamatergic Neurons Derived from the Anterior Hindbrain. *Cell Rep.*
472 33(2), 108268. <https://doi.org/10.1016/j.celrep.2020.108268>
- 473 Morris, G., Maes, M., 2013a. A neuro-immune model of Myalgic Encephalomyelitis/Chronic fatigue
474 syndrome. *Metab. Brain Dis.* 28, 523–540. <https://doi.org/10.1007/s11011-012-9324-8>
- 475 Morris, G., Maes, M., 2013b. Myalgic encephalomyelitis/chronic fatigue syndrome and
476 encephalomyelitis disseminata/multiple sclerosis show remarkable levels of similarity in
477 phenomenology and neuroimmune characteristics. *BMC Med.* 11, 205.
478 <https://doi.org/10.1186/1741-7015-11-205>
- 479 Pendergrast, T., Brown, A., Sunnquist, M., Jantke, R., Newton, J.L., Strand, E.B., Jason, L.A., 2016.
480 Housebound versus nonhousebound patients with myalgic encephalomyelitis and chronic
481 fatigue syndrome. *Chronic Illn.* 12, 292–307. <https://doi.org/10.1177/1742395316644770>
- 482 Perez, M., Jaundoo, R., Hilton, K., Del Alamo, A., Gemayel, K., Klimas, N.G., Craddock, T.J.A.,
483 Nathanson, L., 2019a. Genetic Predisposition for Immune System, Hormone, and Metabolic
484 Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Pilot Study. *Front.*
485 *Pediatr.* 7, 206. <https://doi.org/10.3389/fped.2019.00206>
- 486 Perez, M., Jaundoo, R., Hilton, K., Del Alamo, A., Gemayel, K., Klimas, N.G., Craddock, T.J.A.,
487 Nathanson, L., 2019b. Genetic Predisposition for Immune System, Hormone, and Metabolic
488 Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Pilot Study. *Front.*
489 *Pediatr.* 7.
- 490 Piñero, J., Ramírez-Angueta, J.M., Saüch-Pitarch, J., Ronzano, F., Centeno, E., Sanz, F., Furlong,
491 L.I., 2020. The DisGeNET knowledge platform for disease genomics: 2019 update. *Nucleic*
492 *Acids Res.* 48, D845–D855. <https://doi.org/10.1093/nar/gkz1021>
- 493 Reznikov, L.R., 2017. Cystic Fibrosis and the Nervous System. *Chest* 151, 1147–1155.
494 <https://doi.org/10.1016/j.chest.2016.11.009>
- 495 Ryabkova, V.A., Gavrilova, N.Y., Fedotkina, T.V., Churilov, L.P., Shoenfeld, Y., 2022. Myalgic
496 Encephalomyelitis/Chronic Fatigue Syndrome and Post-COVID Syndrome: A Common
497 Neuroimmune Ground? *Diagn. Basel Switz.* 13, 66.
498 <https://doi.org/10.3390/diagnostics13010066>
- 499 Sharma, A., Menche, J., Huang, C.C., Ort, T., Zhou, X., Kitsak, M., Sahni, N., Thibault, D., Voung,
500 L., Guo, F., Ghiassian, S.D., Gulbahce, N., Baribaud, F., Tocker, J., Dobrin, R., Barnathan,
501 E., Liu, H., Panettieri, R.A., Tantisira, K.G., Qiu, W., Raby, B.A., Silverman, E.K., Vidal, M.,
502 Weiss, S.T., Barabási, A.-L., 2015. A disease module in the interactome explains disease
503 heterogeneity, drug response and captures novel pathways and genes in asthma. *Hum. Mol.*
504 *Genet.* 24, 3005–3020. <https://doi.org/10.1093/hmg/ddv001>
- 505 Spudich, S., Nath, A., 2022. Nervous system consequences of COVID-19. *Science* 375, 267–269.

- 506 <https://doi.org/10.1126/science.abm2052>
507 Suberbielle, E., Djukic, B., Evans, M., Kim, D.H., Taneja, P., Wang, X., Finucane, M., Knox, J., Ho,
508 K., Devidze, N., Masliah, E., Mucke, L., 2015. DNA repair factor BRCA1 depletion occurs in
509 Alzheimer brains and impairs cognitive function in mice. *Nat. Commun.* 6, 8897.
510 <https://doi.org/10.1038/ncomms9897>
511 Thomas, N., Gurvich, C., Huang, K., Gooley, P.R., Armstrong, C.W., 2022. The underlying sex
512 differences in neuroendocrine adaptations relevant to Myalgic Encephalomyelitis Chronic
513 Fatigue Syndrome. *Front. Neuroendocrinol.* 66, 100995.
514 <https://doi.org/10.1016/j.yfrne.2022.100995>
515 Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A.H., Tanaseichuk, O., Benner, C.,
516 Chanda, S.K., 2019. Metascape provides a biologist-oriented resource for the analysis of
517 systems-level datasets. *Nat. Commun.* 10, 1523. <https://doi.org/10.1038/s41467-019-09234-6>

518 **9 Tables**

519 **Table 1. Top 10 biological pathway clusters linked to ME/CFS disease modules.**


Description	# Overlapping genes	LogP	Enrichment	Log(q-value)
Coronavirus disease - COVID-19	92	-90.34	18.14	-87.79
Epstein-Barr virus infection	44	-30.26	9.97	-28.19
Antigen processing and presentation	21	-25.59	32.70	-23.89
MAPK signaling pathway	38	-17.83	5.91	-16.18
Hepatitis B	29	-17.63	8.19	-16.03
Pathways of neurodegeneration - multiple diseases	42	-13.63	4.04	-12.43
Prion disease	33	-14.69	5.53	-13.32
Parkinson disease	29	-11.83	4.99	-10.82
Huntington disease	28	-9.64	4.19	-8.81
Alzheimer disease	30	-8.64	3.57	-7.87
Spinocerebellar ataxia	17	-7.77	5.44	-7.06
Amyotrophic lateral sclerosis	27	-7.37	3.39	-6.71
Diabetic cardiomyopathy	28	-14.01	6.31	-12.77
Thyroid hormone signaling pathway	20	-11.68	7.56	-10.69
Tight junction	15	-10.92	10.78	-9.82
Estrogen signaling pathway	19	-9.70	6.30	-8.85

520

521

522 **10 Figures**


%Alleles	%Individuals	P01	P02	P03	P04	P05	P06	P07	P08	P09	P10	P11	P12	P13	P14	P15	P16	P17	P18	P19	P20	Gene
5.0%	10%			frameshift															frameshift			ACADL
7.5%	15%												frameshift					frameshift	frameshift			BRCA1
5.0%	10%		in-frame					in-frame														CFTR
5.0%	10%						missense														missense	COX10
5.0%	10%				missense										missense							HABP2
17.5%	35%	frameshift	frameshift			frameshift				frameshift	frameshift	frameshift	frameshift					frameshift				MFRP
5.0%	10%						in-frame								in-frame							PCLO
7.5%	15%							missense							stop gain			missense				PRKN
5.0%	10%								missense												missense	ZFPM2

523 

524 Figure 1. Identification of recurrent pathogenic or likely pathogenic variants (using the ACMG
525 criteria) in 20 severely ill ME/CFS patients.

526

527




528

529 Figure 2. Examining the relationship between the SIPS disease module and ME/CFS diagnostic
530 phenotypes, as well as the underlying biological mechanisms. (A) The significance of the enrichment
531 between the SIPS disease module, two ME/CFS underlying conditions (fatigue and cognitive
532 disorders) and six specific neurodegenerative diseases (Prion disease, Parkinson's Disease,
533 Alzheimer's disease, Huntington's disease, Spinocerebellar ataxia, and ALS). The bar plots show
534 fold enrichments, and the colors show the p-values. (B) The interrelationship between the SIPS
535 disease module and neurodegenerative disease pathways from KEGG. The intersection between these
536 two entities is represented in yellow, with the SIPS side in red and the neurodegenerative disease
537 side in blue.

538

539




540

541

542

543 Figure 3. The SIPS and DIAMOND disease modules. (A) The relationship between the SIPS and 70
 544 DIAMOND disease modules, with diseases classified into five categories using Disease Ontology
 545 (Baron et al., 2024) for disease typing. The four categories, excluding cancer, were selected based on
 546 their potential connection to proposed mechanisms of ME/CFS. The similarity measurement is based
 547 on the Jaccard index of overlapping protein interactions. (B) The network representation of the SIPS
 548 disease modules and 70 DIAMOND disease modules, with edges colored according to the category
 549 that used the edge most frequently.

550



551

552 Figure 4. Characterization of the SIPS disease module. (A) The network representation of ME/CFS
553 disease modules, with the depression disease module added for location reference. (B) The largest
554 intra-cluster network component inferred by Metascape from the multi-gene set analysis, with terms
555 not supported by all the ME/CFS disease modules being greyed out.

556

557

558

559